These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

847 related items for PubMed ID: 19486303

  • 1. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A, Takeda S.
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [Abstract] [Full Text] [Related]

  • 2. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT.
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [Abstract] [Full Text] [Related]

  • 3. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.
    BMC Med Genet; 2007 Jul 05; 8():43. PubMed ID: 17612397
    [Abstract] [Full Text] [Related]

  • 4. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.
    Gene Ther; 2006 Oct 05; 13(19):1373-81. PubMed ID: 16724091
    [Abstract] [Full Text] [Related]

  • 5. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ, Graham IR, Malerba A, Dickson G.
    Methods Mol Biol; 2011 Oct 05; 709():153-78. PubMed ID: 21194027
    [Abstract] [Full Text] [Related]

  • 6. Induced dystrophin exon skipping in human muscle explants.
    McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD.
    Neuromuscul Disord; 2006 Oct 05; 16(9-10):583-90. PubMed ID: 16919955
    [Abstract] [Full Text] [Related]

  • 7. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J, Zhang C.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug 05; 28(4):406-8. PubMed ID: 21811980
    [Abstract] [Full Text] [Related]

  • 8. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y, Takeda S.
    Exp Cell Res; 2010 Nov 01; 316(18):3087-92. PubMed ID: 20580709
    [Abstract] [Full Text] [Related]

  • 9. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    J Gene Med; 2009 Mar 01; 11(3):257-66. PubMed ID: 19140108
    [Abstract] [Full Text] [Related]

  • 10. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
    Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJ, Ginjaar HB.
    Neuromuscul Disord; 2010 Apr 01; 20(4):251-4. PubMed ID: 20153965
    [Abstract] [Full Text] [Related]

  • 11. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M.
    Hum Mutat; 2007 Feb 01; 28(2):196-202. PubMed ID: 17041910
    [Abstract] [Full Text] [Related]

  • 12. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G, Fletcher S, Wilton S.
    Curr Opin Pharmacol; 2005 Oct 01; 5(5):529-34. PubMed ID: 16085461
    [Abstract] [Full Text] [Related]

  • 13. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    Ann N Y Acad Sci; 2009 Sep 01; 1175():71-9. PubMed ID: 19796079
    [Abstract] [Full Text] [Related]

  • 14. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD, Flanigan KM.
    Ann Neurol; 2008 Jan 01; 63(1):81-9. PubMed ID: 18059005
    [Abstract] [Full Text] [Related]

  • 15. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Gene Ther; 2004 Sep 01; 11(18):1391-8. PubMed ID: 15229633
    [Abstract] [Full Text] [Related]

  • 16. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M.
    Pediatr Res; 2006 May 01; 59(5):690-4. PubMed ID: 16627883
    [Abstract] [Full Text] [Related]

  • 17. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y, Yokota T.
    Nucleic Acid Ther; 2014 Feb 01; 24(1):57-68. PubMed ID: 24380394
    [Abstract] [Full Text] [Related]

  • 18. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
    Madden HR, Fletcher S, Davis MR, Wilton SD.
    Hum Mutat; 2009 Jan 01; 30(1):22-8. PubMed ID: 18570328
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.
    Mol Ther; 2017 Nov 01; 25(11):2561-2572. PubMed ID: 28865998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.